(chemo)radiotherapy
(Chemo)Radiotherapy — encompassing both radiotherapy (RT) alone and chemoradiotherapy (CRT), in which ionizing radiation is combined with systemic chemotherapeutic agents — represents one of the foundational pillars of modern oncological treatment.
(Chemo)Radiotherapy — encompassing both radiotherapy (RT) alone and chemoradiotherapy (CRT), in which ionizing radiation is combined with systemic chemotherapeutic agents — represents one of the foundational pillars of modern oncological treatment. Radiotherapy leverages high-energy ionizing radiation to induce DNA double-strand breaks, disrupt cellular replication, and drive tumor cell death, while the concurrent or sequential addition of chemotherapy agents (chemoradiotherapy) exploits pharmacological radiosensitization to enhance tumor cell kill beyond what either modality achieves independently. The biological rationale for combining these modalities includes spatial cooperation (chemotherapy targeting distant micrometastases while radiation controls the locoregional disease), temporal cooperation (chemotherapy sensitizing cells to radiation-induced damage), and the exploitation of complementary mechanisms of DNA damage and repair inhibition. (Chemo)Radiotherapy is applied across an exceptionally broad range of malignancies — including head and neck cancers, esophageal squamous cell carcinoma, cervical cancer, diffuse intrinsic pontine glioma, rectal cancer, breast cancer, and prostate cancer — where it functions as a definitive, neoadjuvant, adjuvant, or palliative treatment depending on disease stage and patient factors.
The efficacy of (chemo)Radiotherapy is governed by complex tumor biology, including the capacity of cancer cells to repair radiation-induced DNA damage via pathways such as homologous recombination (HR) and the Shieldin complex, the oxygenation status of the tumor microenvironment, and the molecular landscape of the tumor. Resistance to radiotherapy — radioresistance — remains a critical clinical challenge and is an active focus of translational research, with investigators identifying specific molecular targets such as EZH2, Pol θ (theta), and mitochondrial RNA polymerase as candidate vulnerabilities. Parallel efforts focus on radiosensitization strategies employing small molecules, natural compounds, nanoparticle delivery systems, and emerging physical modalities such as hyperthermia patches.
Where the papers sit
11 papers from the last 6 months study (chemo)radiotherapy directly · updated from PubMed 11 Nov 2026
Study type 1 clinical trial · 4 observational · 4 human data · 1 preclinical · 1 unclassified
Themes no clear themes · 1 new direction
Those 11 do not share a common subject.
-
Diagnosis, radiotherapy, systemic treatment, modeling, and health-economic evaluation appear together across unrelated cancers. Topics include myeloma diagnosis, pancreatic and breast radiotherapy, glioblastoma therapy, prostate cancer mortality, and gastrointestinal cancer treatments. Patient-derived models and organoids address treatment personalization, while other work examines pricing and practice patterns. The set has no single biological question or shared therapeutic direction.
Chemotherapy becomes a set-valued optimal-control problem rather than a fixed treatment input
The leukemic-cell population-dynamics model studied in PMID 42342915 treats chemotherapy not simply as a clinical regimen whose efficacy and toxicity are measured, but as a controllable variable in a mathematical optimization framework. Its stability analysis identifies a continuum of coexistence equilibria and bifurcation thresholds, while the resulting cost functional becomes set-valued, so minimizing leukemia stem cells under toxicity constraints can yield nonunique treatment outcomes. This gives chemotherapy a new role as an optimized, potentially nonunique control policy for navigating population dynamics rather than only as a therapeutic intervention evaluated by response.
Papers
The 11 papers from the last 6 months that study (chemo)radiotherapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (11)
- Non-secretory Multiple Myeloma: A Challenge to Diagnose. Mymensingh medical journal : MMJ · 30 Jun 2026 PMID 42375076
- Potential Role of Proton Beam Therapy for Locally Advanced Pancreatic Cancer. Anticancer research · 29 Jun 2026 PMID 42373264
- Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study. The Lancet. Oncology · 29 Jun 2026 PMID 42372742
- Modeling, Analysis, and Optimal Control of Leukemic Cell Population Dynamics Under Therapy. Bulletin of mathematical biology · 24 Jun 2026 PMID 42342915
- Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O6-methylguanine-DNA methyltransferase glioblastoma: A single-arm, phase 2 study. Cancer · 24 Jun 2026 PMID 42339996
- Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre-Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors. Pharmacoepidemiology and drug safety · 20 Jun 2026 PMID 42322109
- Nanomedicine-Based Therapeutic Approaches in Colorectal Cancer Using Patient-Derived Xenograft Models: Prospects and Challenges. International journal of nanomedicine · 18 Jun 2026 PMID 42311426
- Patient-derived organoids for personalized drug response profiling and multi-omics integration in oral squamous cell carcinoma. iScience · 17 Jun 2026 PMID 42305621
- Value-based pricing of tislelizumab plus chemotherapy versus chemotherapy alone for advanced oesophageal squamous cell carcinoma: a Markov modelling study from the US payer perspective. BMJ open · 27 May 2026 PMID 42203284
- International practice patterns and perceptions of pressurised intraperitoneal aerosol chemotherapy for management of gastric cancer: A global clinician survey. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 22 May 2026 PMID 42173034
- Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and older. Breast cancer research and treatment · 20 May 2026 PMID 42159636
By study type
Clinical trials (1)
- Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O6-methylguanine-DNA methyltransferase glioblastoma: A single-arm, phase 2 study. Cancer · 24 Jun 2026 PMID 42339996
Observational studies and case reports (4)
- Non-secretory Multiple Myeloma: A Challenge to Diagnose. Mymensingh medical journal : MMJ · 30 Jun 2026 PMID 42375076
- Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study. The Lancet. Oncology · 29 Jun 2026 PMID 42372742
- Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre-Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors. Pharmacoepidemiology and drug safety · 20 Jun 2026 PMID 42322109
- Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and older. Breast cancer research and treatment · 20 May 2026 PMID 42159636
Human data, design not indexed (4)
- Potential Role of Proton Beam Therapy for Locally Advanced Pancreatic Cancer. Anticancer research · 29 Jun 2026 PMID 42373264
- Modeling, Analysis, and Optimal Control of Leukemic Cell Population Dynamics Under Therapy. Bulletin of mathematical biology · 24 Jun 2026 PMID 42342915
- Value-based pricing of tislelizumab plus chemotherapy versus chemotherapy alone for advanced oesophageal squamous cell carcinoma: a Markov modelling study from the US payer perspective. BMJ open · 27 May 2026 PMID 42203284
- International practice patterns and perceptions of pressurised intraperitoneal aerosol chemotherapy for management of gastric cancer: A global clinician survey. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 22 May 2026 PMID 42173034
Preclinical: animal, cell and lab studies (1)
- Nanomedicine-Based Therapeutic Approaches in Colorectal Cancer Using Patient-Derived Xenograft Models: Prospects and Challenges. International journal of nanomedicine · 18 Jun 2026 PMID 42311426
Unclassified: not yet indexed with MeSH (1)
- Patient-derived organoids for personalized drug response profiling and multi-omics integration in oral squamous cell carcinoma. iScience · 17 Jun 2026 PMID 42305621
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.